Citation

Hung A, Kim YH, Pavon JM. BMJ 2024; 385: e074892.

Copyright

(Copyright © 2024, BMJ Publishing Group)

DOI

10.1136/bmj-2023-074892

PMID

38719530

Abstract

Polypharmacy is common in older adults and is associated with adverse drug events, cognitive and functional impairment, increased healthcare costs, and increased risk of frailty, falls, hospitalizations, and mortality. Many barriers exist to deprescribing, but increased efforts have been made to develop and implement deprescribing interventions that overcome them. This narrative review describes intervention components and summarizes findings from published randomized controlled trials that have tested deprescribing interventions in older adults with polypharmacy, as well as reports on ongoing trials, guidelines, and resources that can be used to facilitate deprescribing. Most interventions were medication reviews in primary care settings, and many contained components such as shared decision making and/or a focus on patient care priorities, training for healthcare professionals, patient facing education materials, and involvement of family members, representing great heterogeneity in interventions addressing polypharmacy in older adults. Just over half of study interventions were found to perform better than usual care in at least one of their primary outcomes, and most study interventions were assessed over 12 months or less.

Language: en

Keywords

*Deprescriptions; *Polypharmacy; Aged; Drug-Related Side Effects and Adverse Reactions/prevention & control; Humans; Primary Health Care; Randomized Controlled Trials as Topic